Kancera provides operational update in connection with release of financial interim report for third quarter 2023
In connection with the release of the financial interim report for the third quarter of 2023, Kancera AB (publ) provides an operational update regarding its fractalkine blockers KAN567 and KAND145, both in clinical stage. Further, the company reports that...
Read More